Drug Trial Radar · NCT07421297
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
760
Planned (sponsor's estimate)
Start
Feb 28, 2026
Primary completion
Dec 31, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia . This trial plans to enroll 760 Participants.
Conditions
- Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Interventions
SYH2053 injectionDrug
Participants receive SYH2053 injection by subcutaneous administration.
SYH2053 injection placeboOther
Participants receive SYH2053 injection placebo by subcutaneous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in LDL-C relative to baselineTime frame: Day 330
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliation: Peking University Third Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Affiliation: Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.